Valuation : Structure Therapeutics Inc.

Market Cap 2.76B 2.38B 2.25B 2.04B 3.82B 263B 3.84B 26.71B 10.27B 134B 10.35B 10.13B 423B P/E 2026 *
-23.6x
P/E 2027 * -17.8x
Enterprise Value 1.79B 1.54B 1.46B 1.32B 2.48B 171B 2.5B 17.34B 6.67B 86.99B 6.72B 6.57B 275B EV / Sales 2026 *
46.5x
EV / Sales 2027 * 52,739x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Structure Therapeutics Inc.

1 day-2.25%
1 week-18.34%
Current month-15.79%
1 month-28.29%
3 months-9.95%
6 months-29.17%
Current year-44.41%
1 week 38.1
Extreme 38.1
47.38
1 month 38.1
Extreme 38.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 20.04
Extreme 20.04
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 30/04/2022
Chief Executive Officer 62 30/04/2019
Chief Tech/Sci/R&D Officer 52 17/09/2024
Director TitleAgeSince
Director/Board Member 62 31/01/2019
Chairman 68 18/01/2022
Director/Board Member 66 28/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
04/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-18.34%+84.89%+35.79% 2.76B
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.49%-4.49%+36.07%+226.30% 27.32B
Weighted average by Cap. -0.57%-2.98%+31.80%+169.29%

Financials

2026 *2027 *
Net sales 38.46M 33.14M 31.38M 28.44M 53.36M 3.67B 53.63M 373M 143M 1.87B 144M 141M 5.91B 41.67K 35.9K 34K 30.81K 57.81K 3.98M 58.1K 404K 155K 2.03M 156K 153K 6.4M
Net income -314M -270M -256M -232M -435M -29.98B -438M -3.04B -1.17B -15.25B -1.18B -1.15B -48.2B -471M -406M -384M -348M -653M -45B -657M -4.56B -1.76B -22.89B -1.77B -1.73B -72.34B
Net Debt -967M -833M -789M -715M -1.34B -92.4B -1.35B -9.37B -3.6B -47.01B -3.63B -3.55B -149B -559M -482M -456M -414M -776M -53.42B -780M -5.42B -2.08B -27.18B -2.1B -2.05B -85.88B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
11/09/26 US$38.66 -2.25% 1,276,358
10/09/26 US$39.55 -4.07% 761,486
09/09/26 US$41.23 +2.11% 1,562,389
08/09/26 US$40.38 -14.70% 3,417,653
04/09/26 US$47.34 0.00% 281,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
38.66USD
Average target price
105.78USD
Spread / Average Target
+173.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!